Disclosure of Interests: Hilde Berner Hammar Grant/research support from: AbbVie; Pfizer and Roche; Paid instructor for: AbbVie; Pfizer; UB; Novartis, Roche, Speakers bureau: AbbVie; Pfizer; Roche, UB; Novartis, Roche, Brigitte Michelis Grant/research support from: Unrestricted grant; Novartis, Consultant for: Novartis, UC, Sela Rearestad Provant Consultant for: Novartis, Speakers bureau: Lilly, Till Uhlig Consultant for: Grünenthal, Novartis, Speakers bureau: Grünenthal, Novartis, Tore K. Kvien Grant/research support from: AbbVie, BMS, MSD, Pfizer, Roche and UCB., Consultant for: AbbVie, Bio- genes, Biogyn, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Hospira, Merck Serono, MSD, Novartis, Oktal, Orion Pharma, Pfizer, Roche, Sandzo, Sanofi, Mylan and UCB; Speakers bureau: AbbVie, Biogen, BMS, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Hospira, Merck Serono, MSD, Novartis, Oktal, Orion Pharma, Pfizer, Roche, Sandzo, Sanofi and UCB.

Background: Red cell distribution width (RDW) reflects the variation in the circulating erythrocytes size (anisocytosis) that can increase in chronic inflammation due to ineffective erythropoiesis [1], while mean platelet volume (MPV) reveals the average size of platelets and may disclose its activation. Both are typically included in the complete blood count (CBC) and have been studied as a possible indicator of disease activity in many inflammatory conditions [2].

Objectives: This study aimed to assess the relationship between MPV and RDW levels and various rheumatoid arthritis (RA) clinical, laboratory, and ultrasonographic disease activity parameters in patients with recent onset RA before and after initiation of therapy.

Methods: We assessed MPV and RDW in blood samples obtained from 60 recent onset RA patients and 30 healthy controls at baseline and 4 months after initiation therapy with non-biological disease modifying anti-rheumatic drugs (DMARDs). Disease activity was calculated using the 28 joint counts (DAS28) and musculoskeletal ultrasound examination (MSUS) was performed at baseline and after 4 months using a 12-joint score (bilateral elbow, wrist, 2\textsuperscript{nd} metacarpophalangeal (MCP); 3\textsuperscript{rd} MCP, knee, ankle) [2]. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) levels, rheumatoid factor (RF) titre and anti-cyclic citrullinated peptide (anti-CCP) antibodies titre were measured and the health assessment questionnaire (HAQ) score was documented.

Results: Baseline RDW was significantly increased in RA (15.16 ± 3.63%) compared to its level in the healthy controls (12.16 ± 1.43%) (p<0.001). While, there was no significant difference in MPV between RA and control groups (10.92 ± 2.02 fl and 10.08 ± 0.88 fl respectively) (p=0.2). In RA patients, baseline RDW significantly correlated with CRP (r=0.39, p<0.05), DAS28 (r=0.47, p<0.05), grey scale (GS) (r=0.53, p<0.05) and power Doppler (PD) (r=0.56, p<0.001) synovitis scores. Also, RDW at 4 months follow up significantly correlated with the DAS28 (r=0.42, p<0.05), GS score (r=0.45, p<0.05). MPV showed no significant correlation with clinical, laboratory and ultrasonographic parameter of RA disease activity. Baseline RDW (p=0.02) was shown to be comparable to ESR (p=0.03) but less than CRP (p=0.001) at predicting PD synovitis scores.

Conclusion: Rheumatoid arthritis patients have significantly increased RDW levels that remarkably correlated with clinical, laboratory and MSUS parameters of inflammations suggesting that it could be a useful marker to reflect RA disease activity. RDW could be a useful biomarker to predict treatment outcome in RA patient. In this regard, MPV had poor correlations.

REFERENCES


Disclosure of Interests: None declared

AB0258

POTENTIAL ROLE OF MEAN PLATELET VOLUME AND RED BLOOD CELL DISTRIBUTION WIDTH AS A BIOMARKER FOR CLINICAL AND SONOGRAPHIC ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS

Waleed Hassan\textsuperscript{1}, Mourin Elhanafi\textsuperscript{1}, Refaat Eltanawy\textsuperscript{1}, Rehab Shehab El-Din\textsuperscript{2}.

\textsuperscript{1}Bena University, Rheumatology and Rehabilitation, Benha, Egypt. \textsuperscript{2}Kafr elshikh general hospital, Rheumatology and Rehabilitation, Kafr elshikh, Egypt

Background: Among 24767 patients with rheumatoid arthritis, median age at diagnosis is 51 years old and female is 79.2%. The one-year and 5-year mortality rate (per 1000 people) is 41 vs. 177 in CI, 43 vs. 135 in ECI, 43 vs. 169 in M3, 43 vs. 159 in RDCI. Low risk group vs. high risk group The one-year and 5-year mortality rates all are higher in the high risk group compared with low risk group using four comorbidity indexes. The 5-year mortality rate rises up rapidly both in low risk group and high risk group using four comorbidity indexes. The discrimination analysis showed M3 predicted one-year and 5-year mortality best. (Harrell’s c-statistics 0.796 in one-year mortality and 0.802 in 5-year mortality) ECI, M3 and RDCI are all good at predicting mortality as well.

Conclusion: Our study showed mortality rate increased in patients after rheumatoid arthritis was diagnosed. All four comorbidity index score during diagnostic period predicted one-year and 5-year mortality rate well both in high risk and low risk group. Clinicians should screen different comorbidities, determine primary prevention and control disease activity to improve the functional status, quality of life and mortality of rheumatoid arthritis, especially in the patients with initial high risk index score.

REFERENCE

Table 1. 1-year and 5-year mortality analysis for four comorbidity indexes.

<table>
<thead>
<tr>
<th>Comorbidity indexes</th>
<th>1-year mortality rate (per 1000 people)</th>
<th>5-year mortality rate (per 1000 people)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CI</td>
<td>3</td>
<td>41</td>
</tr>
<tr>
<td>High Risk (+1)</td>
<td>23</td>
<td>177</td>
</tr>
<tr>
<td>M3</td>
<td>4</td>
<td>43</td>
</tr>
<tr>
<td>High Risk (+3)</td>
<td>15</td>
<td>135</td>
</tr>
<tr>
<td>M3</td>
<td>4</td>
<td>43</td>
</tr>
<tr>
<td>Low Risk (+1)</td>
<td>19</td>
<td>169</td>
</tr>
<tr>
<td>RDCI</td>
<td>18</td>
<td>159</td>
</tr>
</tbody>
</table>

High risk group for each index was defined as around the top 20% patients.